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Abstract
Background: Electronic cigarettes (ECIGs) are widely used, but their health effects are not well known. ECIG
exposure is difficult to quantify, and a direct measurement of deposition would be beneficial to in vivo and
in vitro toxicity studies. The aim of this study was to demonstrate effective radiolabeling of an ECIG.
Methods: A technetium-99m-labeled carbon ultrafine (TCU) aerosol was generated and introduced to a fourth-
generation ECIG before nucleation and aerosol formation. The aerosolized e-liquid was a commercially available
strawberry flavor containing 1.2% nicotine in a 55% propylene glycol and 45% vegetable glycerine base. An ECIG
power setting of 100 W was selected. Mass and radioactivity were measured on each stage within a Sierra Cascade
Impactor at 14 L/min to verify the labeling technique using the calculated aerodynamic diameters. A strong
positive correlation (R2 > 0.95) between the percent activity and percent mass deposition on each stage provides a
reliable validation of colocation.
Results: Unlabeled ECIG aerosol from the chosen e-liquid produced a mass median aerodynamic diameter
(MMAD) of 0.85 lm. An ECIG labeled with TCU produced an aerosol with an activity median aerodynamic
diameter of 0.84 lm and an MMAD of 0.84 lm. The relative mass versus radioactivity on each plate was highly
correlated (average R2¼ 0.973, p < 0.001).
Conclusion: A TCU radiolabel was generated and shown to associate with the mass of an aerosol produced by a
typical commercially available ECIG. Thus, the radioactivity of the deposited aerosol may be used to determine ECIG
aerosol deposition for the future in vivo and in vitro dosimetry studies of the third- and fourth-generation ECIGs.
Keywords: e-liquid, ECIG, electronic cigarettes, gamma scintigraphy, respiratory deposition imaging, technetium
99m, vaping
Introduction
The potential health effects of short- or long-termelectronic cigarette (ECIG) use are not well known across
the currently available four generations of ECIG devices.(1)
Deposition and imaging studies could connect the in vitro
properties of the aerosol to its toxicology and safety.(2) How-
ever, tools to accurately assess the deposition of ECIG aerosols
in vitro or in vivo are lacking for ECIG users. On a cellular
level, exposure to ECIGs has temporarily reduced ciliary beat
frequency in the same way as traditional cigarettes, which
suggests that repeated ECIG use may damage the lungs over
time.(3) The total and regional respiratory deposition of inhaled
aerosols depends on the mass median aerodynamic diameter
(MMAD), as well as breathing frequency, inhaled volume, and
inhaled flow rate.(4,5) In vivo experiments have defined the
relationship between breathing patterns and respiratory depo-
sition for stable and monodisperse particles with MMADs
between 5 nm and 15 lm.(6) In vitro measurement techniques
such as cascade impaction can be used to guide toxicological
decisions, but these methods are not consistently predictive of
in vivo lung deposition.(7)
An ECIG can be used to generate aerosols containing
nicotine and/or flavoring without the combustion by-products
associated with traditional cigarettes. ECIGs generate aero-
sols by wicking an e-liquid mixture into an electrically heated
coil. Air flows through the center of the coil and the e-liquids
are vaporized in the high temperature region. This vapor is
drawn out of the heating coil by inhalation and droplet for-
mation commences. A single ECIG inhalation contains a
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semivolatile aerosol with condensing/evaporating droplets
and/or nucleating vapor for multiple e-liquid components
simultaneously.(8) Droplet formation occurs through homo-
geneous nucleation.
As collisions within the vapor phase happen more fre-
quently than disintegration, transient agglomerate seeds are
created that are large enough to maintain mass transfer
equilibrium and permit stable growth by condensation.(9)
This aerosolization mechanism can be better understood
through the functional similarity of ECIGs to condensation
aerosol generators.(10)
The objective of this study was to demonstrate effective
radiolabeling of an ECIG for the future in vivo and in vitro
studies. This method was developed from one previously
used to deliver ultrafine carbon technetium-99m particle ag-
gregates to human subjects,(11,12) which was used to quantify
in vivo deposition of aerosols in healthy adults and patients
with chronic obstructive pulmonary disease.(12) Nebulizers,
pressurized metered dose inhalers, and dry powder inhalers
have all been successfully radiolabeled with technetium-99m
(Tc99m) through physical rather than chemical binding to
elucidate the effect of patient population and drug formula-
tion on aerosol delivery.(13)
The goal of our study was to develop a technique for
radiolabeling the fourth-generation ECIG without altering
the aerodynamic properties of the aerosol when compared
with the nonlabeled product. This radiolabeling technique
may allow for the future in vivo measurements of ECIG
aerosol deposition in the respiratory tract using gamma
scintigraphy,(2) a method that has been used to quantify
in vivo total and regional deposition of orally inhaled prod-
ucts in the respiratory tract,(14) but has never been used to
measure in vivo deposition of ECIG aerosols.
Materials and Methods
Radiolabeling of aerosols can often be accomplished by
simply mixing the radioactive material with the liquid to be
aerosolized. ECIGs generate an aerosol by heating a coil to
vaporize a liquid, which rapidly nucleates homogenously and
grows through condensation to form an aerosol. Preliminary
experiments that simply mixed the radioactive material with
the e-liquid failed to radiolabel the ECIG aerosol. Admixing
the label with the e-liquid produced an aerosol whose radio-
active counts on a cascade impactor were not distinguishable
from background radiation, that is, the radioactivity did not
leave the device. The dissolved sodium pertechnetate salt could
not reliably colocate with the aerosol when the ECIG was ac-
tuated in these preliminary experiments (data not shown).
Therefore, the ECIG could not generate the radiolabel by
simply mixing the label with the e-liquid before vaporiza-
tion, and alternative approaches needed to be developed.
Instead, an approach was developed in which aerosols
generated with a fourth-generation ECIG device were mixed
with Tc99m-labeled carbon ultrafine (TCU) particles at the
ECIG air inlet as described in more detail below.
Experimental system selection: ECIG device,
parameters, and liquid
An ECIG has an electrical control system and user in-
terface typically referred to as a box mod. This box mod
transfers energy from a battery source to a heating element
that is housed in the e-liquid reservoir or ‘‘tank.’’ The device
that was used in these experiments was a fourth-generation
ECIG composed of a temperature-controlled box mod (Fuchai
213W; Sigelei, Dongguan, China) paired with an appropriate
tank (Crown 2; Uwell Technologies, City of Industry, CA) that
utilized a 0.25O heating coil. This ECIG used was a popular
model in a local ECIG shop at the time but was purchased online
and is still available from https://www.elementvape.com. A
commercially available strawberry-flavored liquid was pur-
chased from The Vapor Girl Inc. (lot #1523987; Chapel Hill,
NC). It contained 1.2% nicotine in a base fluid composed of 55%
propylene glycol (PG) and 45% vegetable glycerine (VG).
The box mod allowed for adjustment of power supplied to
the coil with an adjustment range of 10W–213W. A power of
100W was selected after preliminary testing at various power
levels recommended by the packaging instructions. This
power level was selected because it was the maximum sug-
gested power, which also produced the maximum amount of
ECIG aerosol. The duration of actuation was chosen to be 10
seconds because of system complexity and the need for timed
coordination. Ten seconds were needed to generate the TCU,
manually switch the TCU flow path, and actuate the ECIG.
The ECIG was actuated twice for 10 seconds each at 100W.
Experimental system selection: generation
of TCU radiolabel
A commercially available generator (Model GFG-1000;
PALAS, Karlsruhe, Germany)(15) was used to generate the
carbon nanoparticle aggregates (20–100 nm) that could be
labeled with Tc99m as was previously described by Brown
et al.(11) This generator has been used previously to study
the deposition and retention of inhaled carbon nanoparticles
in both human and animal studies.(12,16–19) An alternating
high voltage was applied across graphite electrodes in an
argon-filled environment to produce carbon nanoparticles.
The arcing frequency was set to 50 Hz and argon flow at 3 L/
min into an impactor at 14 L/min, which determined both
the concentration(15) of the Tc99m-labeled carbon ultrafine
(TCU) particles (1.2–5.5 mg/m3) and the final activity median
diameter of the ultrafine aerosol (62–87 nm).(11)
The arcing frequency also affected the amount of carbon
vapor output from the PALAS generator. Upon release from
the electrodes into the inert argon gas flowing through the
generator, the carbon vapor condensed into small primary
nanoparticles. From this point on, the primary nanoparticles
steadily coagulated and produced larger particles until sta-
bilized. Two parameters affected the coagulation size: time
until stabilization and the concentration of the vapor. Since
time was essentially held constant by the geometry of the
transport tubing and the flow of the argon gas through it, only
the carbon particle concentration was considered adjustable.
The concentration could be adjusted by the arcing frequency:
the higher the frequency, the higher the particle concentration
and hence the final radiolabel particle size.
The size of the radio-nanoparticle mixed with the e-liquid
vapor will affect its cotransport into the condensing e-liquid
vapor after actuation. Radio-particles that are too large may not
colocate well with the condensing e-liquid but may deliver high
concentrations of radiolabel. However, radio-particles that are
too small may colocate well within the condensed e-liquid after
actuation but may deliver a very small concentration of the
label. An arcing frequency that resulted in sufficient radiolabel
to be used as an inhalation deposition marker in the future
in vivo studies along with satisfactory colocalization in the
e-liquid output was selected from previous studies(11,12) and
tested in a commercially available e-liquid.
A small aliquot (*0.5 mL normal saline solution) con-
taining 10 mCi of sodium pertechnetate was desalted through a
3 mL chromatography column (Poly-Prep Prefilled, AG 50W-
X8 100–200 mesh, hydrogen form; BioRad) and eluted with
distilled water. Sequential aliquots of 0.2 mL were collected
from the column eluent. The four aliquots with the highest
activity were combined, representing about 6 mCi. The eluent
was placed a few drops at a time on the tip of two upright carbon
electrodes from the PALAS carbon nanoparticle generator.
A dry heat blower was directed carefully after each ap-
plication of the pertechnetate solution to the electrode until
the tip was dry. This was repeated until all the pertechnetate
solution had been applied, requiring a total of about 1 hour.
The carbon electrodes were then placed back into position in
the PALAS generator. More complete details regarding the
production of labeled carbon particles can be found in our
previous publication.(11)
Experimental system selection: mixing TCU
radiolabel with ECIG aerosols
The experimental setup incorporated an electronically
controlled three-way valve that changed the path of airflow
during labeling. The first minute of TCU generation was cap-
tured by a filter (Fig. 1a). Then, the three-way valve was
opened, and the TCU was directed into the ECIG where nu-
cleation could occur (Fig. 1b). The duration and timing of flow
switching, ECIG actuation, and TCU production are shown in
Figure 1c. As reported in previous studies,(11,12) the commer-
cial e-liquid was run through a Krypton-85 charge neutralizer
(Model 3012; TSI Incorporated, St. Paul, MN) to eliminate any
TCU particle charge that may have been induced by sparking
the carbon electrodes. To determine the effect of charge
FIG. 1. System schematic and timing diagram for radiolabeled ECIG
aerosol delivery. The three-way valve was (a) closed to direct the technetium
carbon ultrafine aggregates directly to a filter or (b) open to direct the tech-
netium carbon ultrafine aggregates to the ECIG for labeling. The timeline (c)
outlines the actuation parameters used to minimize collection of label not
associated with ECIG aerosol. ECIG, electronic cigarette.
FIG. 2. The custom connector (a) is shown with dimen-
sions in millimeters. The dashed hidden lines represent
channels that allow airflow into the heating region by four
vent inlets. The section view along the plane A-A shows the
wall thickness of the connector by diagonal lines. The
custom connector and the fourth-generation ECIG assembly
(b) are shown with the connector sealed over the air inlets.
neutralization on the radiolabeling process, the results from
those experiments were compared with the results from ex-
periments that did not use the charge neutralizer.
An aerosol containing ultrafine carbon particle aggregates
was radiolabeled with Tc99m-labeled carbon ultrafine (TCU)
and introduced via a novel, but simple connector at the ECIG
air inlet. The ultrafine aerosol was presented to the ECIG im-
mediately upon actuation and was routed away before the end
of actuation to clear the ECIG and connectors of TCU. The
investigators designed and three-dimensional printed the cus-
tom connector illustrated with the dimensions specified in
Figure 2a. The tight fit ensured a seal over the air inlet vents of
the ECIG. The custom connector allowed for ultrafine particles
to be precisely introduced before the site of nucleation within
the ECIG (Fig. 2b). As ECIG design evolves, the connector
may need to be adapted to the dimensions of a new ECIG
mouthpiece.
Analysis of radiolabeled ECIG aerosol generation
An eight-stage Sierra Series 210 Cascade Impactor (Sierra
Instruments, Carmel Valley, CA) was operated at 14 L/min
to determine the MMAD gravimetrically and activity median
aerodynamic diameter (AMAD) using a single crystal (NaI)
scintillation detector (Model LMS-44; Nuclear Data, Inc.,
Smyrna, GA). This flow rate is one of the recommended flow
rates for operation and one for which stage cutoff sizes are
clearly provided. The 50% collection efficiency for the im-
pactor stages span aerodynamic diameters from 0.15 to 13 lm
at 14 L/min and are provided in Table 1.
The single crystal detector was placed a few inches from
each impactor plate and counted for radioactivity in their
sequential order, with distance from the plates kept constant.
Radioactive counts deposited on each plate were used to
calculate the AMAD of the particles found in the impactor
according to the manufacturer’s manual.
It has been proposed that the acceptability of a radiolabeling
method for regional deposition requires that the mean ratio of
the radiolabeled drug to the reference drug should be within
0.85–1.18 per group of impactor stages with at least four groups
or within –2% if the deposited fraction of unlabeled aerosol is
<10%.(20) The reference drug for this study was the unlabeled
commercial e-liquid. In addition to testing the unlabeled ECIG,
the distribution of mass and activity fractions of the labeled
ECIG aerosol across the stages of the cascade impactor were
partitioned into seven bins with bin 1 containing the filter; bin 2
containing stage 8; bin 3 containing stage 7; bin 4 containing
stages 6, 5, and 4; bin 5 containing stage 3; bin 6 containing
stage 2; and bin 7 containing stage 1. This is summarized in
Table 1.
Grouping the deposition in seven bins instead of the mini-
mum suggested four bins highlights the quality of the la-
beling method and demonstrates the ability to produce a
radiolabeled ECIG aerosol in which the activity follows the
mass for the majority of the mass.
To validate colocalization of radio-label versus the mass of
the deposited aerosol, an R2 value >0.95 was deemed accept-
able. The R2 value was determined from a simple linear re-
gression of the mass of the deposited aerosol versus the activity
of the label found on the stages of the Sierra impactor.
Results
Baseline unlabeled ECIG aerosol size distributions for the
commercial e-liquid were measured in four replicate experi-
ments. The average (standard deviation [SD]) MMAD of the
commercial e-liquid emitted by the ECIG was 0.85 (0.00) lm.
Mass-based sizing of the commercial e-liquid radiolabeled at
50 Hz resulted in an average (SD) MMAD of 0.84 (0.02) lm.
These values and the corresponding geometric standard de-
viations are summarized in Table 2. Activity-based mea-
surements were made using the same impactor techniques as
mass-based measurements. When the TCU was introduced
into an actuated ECIG, the average (SD) AMAD of the
commercial e-liquid was 0.84 (0.01) lm.
The potential effect of TCU charge on ECIG particle size
showed that the average (SD) MMAD of the ECIG aerosol
with and without the charge neutralizer was 0.83 (0.02) and
0.85 (0.02) lm, respectively (Fig. 3). The mean (SD) AMAD
of the ECIG aerosol with and without the charge neutralizer
were 0.84 (0.02) and 0.84 (0.01) lm, respectively. The charge
neutralizer was observed to have no effect on the output.
Additional aerosol characteristics for the charge neutralizer
experiments are listed in Table 3.
Table 1. Stage Cutoff Diameters Associated
with the Sierra 210 Cascade Impactor
and the Corresponding Grouping Assignments
to Bins for Analysis
Stage No. Cutoff diameter (lm) Grouping
Filter N/A Bin 1
8 0.15 Bin 2
7 0.34 Bin 3
6 0.63 Bin 4
5 1.2 Bin 4
4 1.8 Bin 4
3 3.1 Bin 5
2 7.8 Bin 6
1 13 Bin 7
N/A, not applicable.
Table 2. Aerosol Size Characteristics of a Commercially Available Strawberry-Flavored
e-Liquid Containing 1.2% Nicotine, 55% Propylene Glycol, and 45% Vegetable Glycerine









Unlabeled 0.85 – 0.00 1.46 – 0.01 N/A N/A N/A 4
Labeled 0.84 – 0.02 1.48 – 0.01 0.84 – 0.01 1.69 – 0.04 0.973 – 0.01 7
AMAD, activity median aerodynamic diameter; GSD, geometric standard deviation; MMAD, mass median aerodynamic diameter.
The linearity of mass fraction versus activity fraction de-
scribes the association between the label and the bulk aerosol.
The mean (SD) of R2 values was 0.973 (0.01) for the com-
mercial strawberry-flavored e-liquid with 1.2% nicotine in a
55% PG/45% VG base. These values demonstrate the ro-
bustness of the labeling method.
The mass distributions in the unlabeled ECIG were com-
pared with the mass and activity distributions in the radi-
olabeled ECIG (Fig. 4) and were within the suggested
acceptance criteria for all bins except for bin 2. The ratio of
labeled mass to unlabeled mass in bin 4 was 0.968. The
unlabeled aerosol had 7.3% mass deposited in bin 2, which
produce the acceptance criteria(20) of 5.3%–9.3%. The la-
beled mass fraction was within this acceptance criteria at
8.3%. The labeled activity deposited in bin 2 was 11.8%,
meaning that the labeled activity was 2.5% above the
guidelines provided for bin 2.
Discussion
Dosimetry and toxicology of ECIG aerosols could be better
understood by in vivo studies, but there are few tools available
to quantitatively assess ECIG aerosol deposition. The meth-
ods implemented in this study provide a radiolabeling tech-
nique that can be used to measure the deposited dose of ECIGs
for toxicology studies and supply benchmark data for the
future in silico work. Unlabeled ECIG aerosol measurements
of MMAD were similar to radiolabeled ECIG aerosols for the
commercial e-liquid. Labeling the commercial e-liquid pro-
duced an aerosol with a similar mass distribution to that of the
unlabeled reference (Table 2). The introduction of the ra-
diolabel to the ECIG aerosol did not alter the aerosol distri-
bution for the conditions considered.
Repeated measurements of the ECIG formulation demon-
strated a low SD and consistent methodology. Future studies
could use this approach to measure the size distribution for
aerosols produced by other e-liquids and devices. Previous im-
pactor measurements of ECIG aerosols have shown MMADs
ranging from 0.53 to 0.96 lm.(21) Results from the present
study are within that range. Other methods of measurements
that did not collect the entire generated semivolatile aerosol
resulted in smaller MMADs (0.12–0.18 lm).(22,23) This is
expected due to the large air dilution volumes and sampling
required for the measurement techniques employed in these
previous studies.
When the TCU label passed through the aerosol generation
region (heating coil) of the ECIG, the diameter shifted from
the expected 0.06–0.09 lm to 0.84 lm. The TCU successfully
provided nucleation sites for the condensing e-liquid and
produced AMADs that were much larger than the initial TCU
aerosol size. The TCU was shown to associate with the ECIG
aerosol in (1) the measured AMAD of 0.84 lm, (2) the
agreement between the AMADs and MMADs for the com-
mercial e-liquid, and (3) the linear relationship between mass
and activity fractions having an R2 of >0.95.
Greater than 99% of the radioactivity, as well as the la-
beled and unlabeled mass of the aerosol, was in the fine
particle fraction, as shown in Figure 4. A single bin in
Figure 4 was slightly greater than the suggested –2% ac-
ceptance criterion defined by Devadason et al.(20) for de-
position fractions of unlabeled mass <10%. The suggested
acceptance criterion(20) of a mass and activity ratio of 0.85–
1.18 was met by all bins with deposition fractions >10%.
The labeled activity measurement in bin 2 in Figure 4 was
likely higher than the reference mass measurement due
to evaporation of the deposited mass.
Previous studies have charge neutralized the TCU ag-
glomerate before subject inhalation.(11,12) The use of the
charge neutralizer in our study had no effect on the aerody-
namic diameter as measured by mass or activity. Removing
the charge neutralizer reduces complexity and makes it easier
for this inhalation technique to be replicated by additional
researchers without affecting the validity of the method.
FIG. 3. Cascade impactor measurements of radiolabeled
ECIG with and without a charge neutralizer. The counts on
each stage were divided by the total number of counts to
determine the % counts. Error bars represent 1 standard
deviation in n ‡ 3 replicates.
Table 3. Cascade Impactor Measurements Used to Determine the Necessity of Electrically
Neutralizing the Radioactive Aerosol Before Labeling the Electronic Cigarette Containing
a Commercially Available Strawberry Flavored e-Liquid Composed of 1.2% Nicotine,











Without charge neutralizer 0.85 – 0.02 0.84 – 0.01 1.49 – 0.03 1.69 – 0.08 467.2 – 24.8 0.973 – 0.02
With charge neutralizer 0.83 – 0.02 0.84 – 0.02 1.48 – 0.01 1.69 – 0.02 469.5 – 29.6 0.973 – 0.01
The ECIG radiolabeling method developed here has the
potential to investigate in vivo aerosol deposition within the
respiratory tract, validate in silico and in vitro deposition
models, and quantify ECIG aerosol deposition in in vitro cel-
lular work. The mechanism of deposition for stable monodis-
perse aerosols with MMADs similar to the present study are
expected to be equivalent,(6) but the size of the semivolatile
aerosol produced by an ECIG could change over time due to
evaporation and condensation in the lungs.
To test the effect of condensational growth, radiolabeled
ECIG aerosol deposition could be measured in a study de-
signed to compare regional deposition of e-liquids with
different ratios of PG/VG, which could differ due to con-
densational growth of the aerosol in the respiratory tract.
In vivo regional deposition data could also be used to vali-
date and improve numerical predictions of ECIG aerosol
dosimetry.(8) Finally, quantifying the radiolabeled ECIG de-
livery to in vitro cell cultures could allow for better charac-
terization of the dose–response associated with the ECIG
toxicity in these in vitro models.(24)
In conclusion, a method for radiolabeling an ECIG aero-
sol was developed and tested in a commercially available
strawberry-flavored e-liquid containing 1.2% nicotine and
55% PG and 45% VG. One limitation of the current system
is the 10-second puff duration. This will be reduced to re-
alistic puff durations in the future studies by streamlining
and automating the three-way valve switching system. This
automation will also allow consistent timing of label de-
livery when operated by ECIG users in vivo. For shorter puff
durations, an arcing frequency of 100 Hz, with its higher
activity output, is suggested. Implementation of the new TCU-
ECIG labeling system is recommended as a useful tool for
characterizing the deposition of aerosols produced by ECIGs
in the future in vivo or in vitro studies.
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